SK Bioscience Co

SK Bioscience Co Equity

The The Equity of SK Bioscience Co (302440.KS) as of Nov 2, 2026 is 1.79 T KRW. In the previous year, The Equity was 1.80 T KRW — a change of -0.76% (lower).

Equity

1.79 TKRW

YoY

-0.76%

Last updated:

In 2025, SK Bioscience Co's equity was 1.79 T KRW, a -0.76% increase from the 1.80 T KRW equity in the previous year.

The SK Bioscience Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
210.73 B KRW
Jan 1, 2019
232.73 B KRW
Jan 1, 2020
263.79 B KRW
Jan 1, 2021
1.60 T KRW
Jan 1, 2022
1.74 T KRW
Jan 1, 2023
1.70 T KRW
Jan 1, 2024
1.80 T KRW
Jan 1, 2025
1.79 T KRW
The SK Bioscience Co Equity history
YEAREquityYoY
1.79 TKRW-0.76%
1.80 TKRW+5.79%
1.70 TKRW-2.17%
1.74 TKRW+8.77%
1.60 TKRW+507.04%
263.79 BKRW+13.34%
232.73 BKRW+10.44%
210.73 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing SK Bioscience Co's Equity

SK Bioscience Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SK Bioscience Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SK Bioscience Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SK Bioscience Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SK Bioscience Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SK Bioscience Co stock

The Equity of SK Bioscience Co is 1.79 T KRW in 2025.

The Equity of SK Bioscience Co changed from 1.80 T KRW to 1.79 T KRW, representing a -0.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's SK Bioscience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SK Bioscience Co

All Key Metrics — SK Bioscience Co